

# Luis Alvarez-Vallina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8642853/publications.pdf>

Version: 2024-02-01

101  
papers

3,377  
citations

172457

29  
h-index

168389

53  
g-index

103  
all docs

103  
docs citations

103  
times ranked

4544  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer. <i>Oncolimmunology</i> , 2022, 11, 2034355.	4.6	21
2	Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers. <i>Cancer Immunology Research</i> , 2022, 10, 498-511.	3.4	12
3	Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies. <i>Oncolimmunology</i> , 2022, 11, 2054106.	4.6	7
4	Applications of trimerbodies in cancer immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2022, , 71-87.	3.2	0
5	An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity. <i>Clinical Cancer Research</i> , 2021, 27, 3167-3177.	7.0	16
6	Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. <i>Communications Biology</i> , 2021, 4, 310.	4.4	29
7	Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5457-5464.	7.0	59
8	P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas. <i>Nature Communications</i> , 2021, 12, 3615.	12.8	25
9	Engineered mRNA and the Rise of Next-Generation Antibodies. <i>Antibodies</i> , 2021, 10, 37.	2.5	8
10	TGF $\beta$ 2-induced IGFBP3 is a key paracrine factor from activated pericytes that promotes colorectal cancer cell migration and invasion. <i>Molecular Oncology</i> , 2020, 14, 2609-2628.	4.6	18
11	Perforin gene variant A91V in young patients with severe COVID-19.. <i>Haematologica</i> , 2020, 105, 2844-2846.	3.5	16
12	Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies. <i>Frontiers in Immunology</i> , 2020, 11, 1792.	4.8	14
13	Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential. <i>Frontiers in Oncology</i> , 2020, 10, 593848.	2.8	12
14	Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR. <i>Frontiers in Immunology</i> , 2020, 11, 614363.	4.8	5
15	Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies. <i>Frontiers in Immunology</i> , 2019, 10, 1791.	4.8	19
16	The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications. <i>European Journal of Cancer</i> , 2019, 123, 118-129.	2.8	50
17	A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts. <i>Scientific Reports</i> , 2019, 9, 11680.	3.3	25
18	Immuno-PET Imaging and Pharmacokinetics of an Anti-CEA scFv-based Trimerbody and Its Monomeric Counterpart in Human Gastric Carcinoma-Bearing Mice. <i>Molecular Pharmaceutics</i> , 2019, 16, 1025-1035.	4.6	21

#	ARTICLE	IF	CITATIONS
19	T Cell-Redirecting Strategies to $\hat{\infty}$ STAb $\hat{\infty}$ ™ Tumors: Beyond CARs and Bispecific Antibodies. Trends in Immunology, 2019, 40, 243-257.	6.8	32
20	Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy. Frontiers in Cell and Developmental Biology, 2019, 7, 370.	3.7	25
21	ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. Oncoimmunology, 2018, 7, e1377874.	4.6	56
22	A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. Nature Communications, 2018, 9, 4809.	12.8	116
23	Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies. Cancer Immunology, Immunotherapy, 2018, 67, 1251-1260.	4.2	20
24	Balanced secretion of anti-CEA $\hat{\infty}$ anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity. Gene Therapy, 2017, 24, 208-214.	4.5	14
25	Immune Regulation by Pericytes: Modulating Innate and Adaptive Immunity. Frontiers in Immunology, 2016, 7, 480.	4.8	108
26	Role of nucleotide-binding oligomerization domain 1 (<scp>NOD</scp>1) in pericyte-mediated vascular inflammation. Journal of Cellular and Molecular Medicine, 2016, 20, 980-986.	3.6	22
27	Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity?. Biochemical Society Transactions, 2016, 44, 406-411.	3.4	18
28	Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains. Scientific Reports, 2016, 6, 28643.	3.3	26
29	Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies. AMB Express, 2015, 5, 137.	3.0	2
30	The coming of age of engineered multivalent antibodies. Drug Discovery Today, 2015, 20, 588-594.	6.4	114
31	Selection strategies for anticancer antibody discovery: searching off the beaten path. Trends in Biotechnology, 2015, 33, 292-301.	9.3	29
32	In vivo secretion of anti-CD3 $\hat{\infty}$ anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement. Molecular Therapy, 2015, 23, 612-613.	8.2	0
33	Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management. Journal of Drug Targeting, 2015, 23, 170-179.	4.4	24
34	Programming Controlled Adhesion of <i>E. coli</i> to Target Surfaces, Cells, and Tumors with Synthetic Adhesins. ACS Synthetic Biology, 2015, 4, 463-473.	3.8	133
35	Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications. Oncoimmunology, 2014, 3, e28810.	4.6	30
36	Lipopolysaccharide Activates Toll-like Receptor 4 (TLR4)-mediated NF- $\hat{\infty}$ B Signaling Pathway and Proinflammatory Response in Human Pericytes. Journal of Biological Chemistry, 2014, 289, 2457-2468.	3.4	227

#	ARTICLE	IF	CITATIONS
37	Efficient production of single-chain fragment variable-based N-terminal trimerbodies in <i>Pichia pastoris</i> . <i>Microbial Cell Factories</i> , 2014, 13, 116.	4.0	12
38	Científicos españoles con los Dres. Greg Winter y Richard A. Lerner, premios Príncipe de Asturias en Investigación Científica y Técnica 2012. <i>Inmunología</i> (Barcelona, Spain: 1987), 2013, 32, 70-74.	0.1	0
39	Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. <i>Medical Oncology</i> , 2013, 30, 572.	2.5	21
40	The Efficacy Versus Toxicity Profile of Combination Virotherapy and TLR Immunotherapy Highlights the Danger of Administering TLR Agonists to Oncolytic Virus-treated Mice. <i>Molecular Therapy</i> , 2013, 21, 348-357.	8.2	33
41	In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells. <i>Antibodies</i> , 2013, 2, 415-425.	2.5	1
42	Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13791-13796.	7.1	26
43	Immunotherapeutic organoids. <i>Biomatter</i> , 2013, 3, e23897.	2.6	9
44	Generation and characterization of monospecific and bispecific hexavalent trimerbodies. <i>MAbs</i> , 2013, 5, 70-79.	5.2	30
45	CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e93.	5.1	30
46	Antibody Gene Therapy: Getting Closer to Clinical Application?. <i>Current Gene Therapy</i> , 2013, 13, 282-290.	2.0	21
47	Basement Membrane-Rich Organoids with Functional Human Blood Vessels Are Permissive Niches for Human Breast Cancer Metastasis. <i>PLoS ONE</i> , 2013, 8, e72957.	2.5	15
48	In vivo selection of tumor-specific antibodies. <i>Oncotarget</i> , 2013, 4, 1547-1547.	1.8	3
49	Improved stability of multivalent antibodies containing the human collagen XV trimerization domain. <i>MAbs</i> , 2012, 4, 226-232.	5.2	27
50	Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. <i>Oncolimmunology</i> , 2012, 1, 1344-1354.	4.6	8
51	Dr. Gregory Winter y Dr. Richard A. Lerner, Premios Príncipe de Asturias de Investigación Científica y Técnica 2012. <i>Inmunología</i> (Barcelona, Spain: 1987), 2012, 31, 127-134.	0.1	0
52	The Heterotrimeric Laminin Coiled-Coil Domain Exerts Anti-Adhesive Effects and Induces a Pro-Invasive Phenotype. <i>PLoS ONE</i> , 2012, 7, e39097.	2.5	8
53	Non-hematopoietic stem cells as factories for in vivo therapeutic protein production. <i>Gene Therapy</i> , 2012, 19, 1-7.	4.5	19
54	The axonal repellent Slit2 inhibits pericyte migration: Potential implications in angiogenesis. <i>Experimental Cell Research</i> , 2012, 318, 371-378.	2.6	34

#	ARTICLE	IF	CITATIONS
55	The therapeutic potential of engineered human neovessels for cell-based gene therapy. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 67-76.	3.1	5
56	New trends in immunotherapy. <i>Inmunologia (Barcelona, Spain: 1987)</i> , 2011, 30, 128-134.	0.1	0
57	Engineered human tumor xenografts with functional human vascular networks. <i>Microvascular Research</i> , 2011, 81, 18-25.	2.5	9
58	Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins. <i>Current Opinion in Biotechnology</i> , 2011, 22, 924-930.	6.6	15
59	The Multicompartmental p32/gClqR as a New Target for Antibody-based Tumor Targeting Strategies. <i>Journal of Biological Chemistry</i> , 2011, 286, 5197-5203.	3.4	40
60	The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies.. <i>Journal of Biological Chemistry</i> , 2011, 286, 22706.	3.4	1
61	Multivalent antibodies: when design surpasses evolution. <i>Trends in Biotechnology</i> , 2010, 28, 355-362.	9.3	172
62	Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system. <i>Gene Therapy</i> , 2010, 17, 745-751.	4.5	25
63	In Vivo Tumor Targeting and Imaging with Engineered Trivalent Antibody Fragments Containing Collagen-Derived Sequences. <i>PLoS ONE</i> , 2009, 4, e5381.	2.5	56
64	Lymphocyte Display: A Novel Antibody Selection Platform Based on T Cell Activation. <i>PLoS ONE</i> , 2009, 4, e7174.	2.5	16
65	Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts. <i>Laboratory Investigation</i> , 2009, 89, 91-97.	3.7	32
66	Tumor Immunotherapy Using Gene-Modified Human Mesenchymal Stem Cells Loaded into Synthetic Extracellular Matrix Scaffolds. <i>Stem Cells</i> , 2009, 27, 753-760.	3.2	89
67	Functionally fused antibodies—A novel adjuvant fusion system. <i>Journal of Immunological Methods</i> , 2008, 339, 220-227.	1.4	0
68	Long-term in vivo imaging of human angiogenesis: Critical role of bone marrow-derived mesenchymal stem cells for the generation of durable blood vessels. <i>Microvascular Research</i> , 2008, 75, 308-314.	2.5	77
69	Comment on “Production of multivalent protein binders using a self-trimerization collagen-like peptide scaffold”. <i>FASEB Journal</i> , 2008, 22, 3417-3417.	0.5	0
70	Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA – anti-CD3 diabodies from lentivirally transduced human lymphocytes. <i>Cancer Gene Therapy</i> , 2007, 14, 380-388.	4.6	60
71	Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I. <i>Immunology</i> , 2006, 117, 502-506.	4.4	15
72	Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. <i>International Journal of Cancer</i> , 2006, 119, 455-462.	5.1	30

#	ARTICLE	IF	CITATIONS
73	Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. <i>Biochemical Journal</i> , 2005, 387, 231-238.	3.7	22
74	Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells. <i>Cancer Gene Therapy</i> , 2005, 12, 464-474.	4.6	7
75	Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. <i>Cancer Gene Therapy</i> , 2005, 12, 900-912.	4.6	32
76	Antibody engineering: facing new challenges in cancer therapy. <i>Acta Pharmacologica Sinica</i> , 2005, 26, 641-648.	6.1	56
77	Establishment of an immortalized PARP-1 <sup>-/-</sup> murine endothelial cell line: A new tool to study PARP-1 mediated endothelial cell dysfunction. <i>Journal of Cellular Biochemistry</i> , 2005, 94, 1163-1174.	2.6	3
78	Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?. <i>Current Gene Therapy</i> , 2005, 5, 63-70.	2.0	10
79	Full Activation of PKB/Akt in Response to Insulin or Ionizing Radiation Is Mediated through ATM. <i>Journal of Biological Chemistry</i> , 2005, 280, 4029-4036.	3.4	231
80	Selection of functional human antibodies from retroviral display libraries. <i>Nucleic Acids Research</i> , 2005, 33, e35-e35.	14.5	34
81	Antibody-based antiangiogenic cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 1235-1245.	3.4	6
82	Antibodies and gene therapy: teaching old "magic bullets" new tricks. <i>Trends in Immunology</i> , 2004, 25, 85-91.	6.8	87
83	A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis. <i>EMBO Journal</i> , 2003, 22, 1508-1517.	7.8	23
84	Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 643-647.	4.2	18
85	Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system. <i>Cancer Gene Therapy</i> , 2003, 10, 152-160.	4.6	10
86	The extracellular matrix: a new turn-of-the-screw for anti-angiogenic strategies. <i>Trends in Molecular Medicine</i> , 2003, 9, 256-262.	6.7	21
87	Induction of Human T Lymphocyte Cytotoxicity and Inhibition of Tumor Growth by Tumor-Specific Diabody-Based Molecules Secreted from Gene-Modified Bystander Cells. <i>Journal of Immunology</i> , 2003, 171, 1070-1077.	0.8	55
88	Cells as Vehicles for Cancer Gene Therapy: The Missing Link Between Targeted Vectors and Systemic Delivery?. <i>Human Gene Therapy</i> , 2002, 13, 1263-1280.	2.7	79
89	Development of a Computer-Assisted High-Throughput Screening Platform for Anti-angiogenic Testing. <i>Microvascular Research</i> , 2002, 63, 335-339.	2.5	30
90	Functional improvement of antibody fragments using a novel phage coat protein III fusion system. <i>Biochemical and Biophysical Research Communications</i> , 2002, 298, 566-573.	2.1	26

#	ARTICLE	IF	CITATIONS
91	Autocrine costimulation: Tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein. <i>Cancer Gene Therapy</i> , 2002, 9, 275-281.	4.6	12
92	Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. <i>Gene Therapy</i> , 2002, 9, 1049-1053.	4.5	48
93	Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. <i>Nature Biotechnology</i> , 2002, 20, 256-263.	17.5	30
94	Genetic Approaches for Antigen-Selective Cell Therapy. <i>Current Gene Therapy</i> , 2001, 1, 385-397.	2.0	31
95	Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 557-565.	4.2	28
96	Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors. <i>Cancer Gene Therapy</i> , 2000, 7, 526-529.	4.6	10
97	Efficient Discrimination between Different Densities of Target Antigen by Tetracycline-Regulatable T Bodies. <i>Human Gene Therapy</i> , 1999, 10, 559-563.	2.7	20
98	Delay in resumption of the activity of tetracycline-regulatable promoter following removal of tetracycline analogues. <i>Gene Therapy</i> , 1997, 4, 993-997.	4.5	37
99	Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. <i>European Journal of Immunology</i> , 1996, 26, 2304-2309.	2.9	115
100	Isolation of Tumor-Derived Immunoglobulin-Idiotypic from Peripheral Blood Mononuclear Cells in a B-Cell Lymphoma Patient with Minimal Disease. <i>Journal of Immunotherapy</i> , 1995, 17, 194-198.	2.4	1
101	4-1BB-mediated cancer immunotherapy: "mission impossible" for non-engineered IgGs?. <i>Precision Cancer Medicine</i> , 0, 2, 1-1.	1.8	3